Evaluation of body-surface-area adjusted dosing of high-dose methotrexate by population pharmacokinetics in a large cohort of cancer patients
Open Access
- 20 June 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 21 (1), 1-10
- https://doi.org/10.1186/s12885-021-08443-x
Abstract
Background: The aim of this study was to identify sources of variability including patient gender and body surface area (BSA) in pharmacokinetic (PK) exposure for high-dose methotrexate (MTX) continuous infusion in a large cohort of patients with hematological and solid malignancies. Methods: We conducted a retrospective PK analysis of MTX plasma concentration data from hematological/oncological patients treated at the University Hospital of Cologne between 2005 and 2018. Nonlinear mixed effects modeling was performed. Covariate data on patient demographics and clinical chemistry parameters was incorporated to assess relationships with PK parameters. Simulations were conducted to compare exposure and probability of target attainment (PTA) under BSA adjusted, flat and stratified dosing regimens. Results: Plasma concentration over time data (2182 measurements) from therapeutic drug monitoring from 229 patients was available. PK of MTX were best described by a three-compartment model. Values for clearance (CL) of 4.33 [2.95–5.92] L h− 1 and central volume of distribution of 4.29 [1.81–7.33] L were estimated. An inter-occasion variability of 23.1% (coefficient of variation) and an inter-individual variability of 29.7% were associated to CL, which was 16 [7–25] % lower in women. Serum creatinine, patient age, sex and BSA were significantly related to CL of MTX. Simulations suggested that differences in PTA between flat and BSA-based dosing were marginal, with stratified dosing performing best overall. Conclusion: A dosing scheme with doses stratified across BSA quartiles is suggested to optimize target exposure attainment. Influence of patient sex on CL of MTX is present but small in magnitude.Keywords
Funding Information
- Universitätsklinikum Köln
This publication has 49 references indexed in Scilit:
- Drug Dosing Based on Weight and Body Surface Area: Mathematical Assumptions and Limitations in Obese AdultsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2012
- Covariate Pharmacokinetic Model Building in Oncology and its Potential Clinical RelevanceThe AAPS Journal, 2012
- A Population Pharmacokinetic/Pharmacodynamic Model of Methotrexate and Mucositis Scores in OsteosarcomaTherapeutic Drug Monitoring, 2011
- Piraña and PCluster: A modeling environment and cluster infrastructure for NONMEMComputer Methods and Programs in Biomedicine, 2011
- Germline Genetic Variation in an Organic Anion Transporter Polypeptide Associated With Methotrexate Pharmacokinetics and Clinical EffectsJournal of Clinical Oncology, 2009
- Advances in individual prediction of methotrexate toxicity: a reviewBritish Journal of Haematology, 2009
- Population Pharmacokinetics of High-Dose Methotrexate After Intravenous Administration in Pediatric Patients With OsteosarcomaTherapeutic Drug Monitoring, 2009
- Population Pharmacokinetics of High-Dose Methotrexate in Children with Acute Lymphoblastic LeukaemiaClinical Pharmacokinetics, 2006
- Bayesian Estimation of Methotrexate Pharmacokinetic Parameters and Area Under the Curve in Children and Young Adults with Localised OsteosarcomaClinical Pharmacokinetics, 2002
- The importance of modeling interoccasion variability in population pharmacokinetic analysesJournal of Pharmacokinetics and Biopharmaceutics, 1993